Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer

Abstract excerpt

Abstract Gemcitabine is the first-line treatment for locally advanced and metastatic gallbladder cancer (GBC), but poor gemcitabine response is universal. Here, we utilize a genome-wide CRISPR screen to identify that loss of ELP5 reduces the gemcitabine-induced apoptosis in GBC cells in a P53-dependent manner through the Elongator complex and other uridine 34 (U34) tRNA-modifying enzymes. Mechanistically, loss of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cholangiocarcinoma and Gallbladder Cancer Studies
• Share to Peptidase Inhibition and Analysis
• Share to RNA modifications and cancer